



Terumo Announces Change of Representative Directors

TOKYO, JAPAN – February 9, 2017 – Terumo Corporation (TSE: 4543) hereby announces that its Board of Directors meeting held on February 9, 2017 has resolved a change of its Representative Directors as follows.

1. Change of Representative Directors (As of April 1, 2017)

Name	New Title	Current Title
Yutaro Shintaku	Director and Corporate Advisor	President and CEO (Representative Director)
Hiroshi Matsumura	Director and Corporate Advisor	Representative Director and Executive Vice President

As the announcement on December 15, 2016, Terumo appointed Takayoshi Mimura as new Chairman of the Board (Representative Director) and Shinjiro Sato as new President and CEO (Representative Director). (The scheduled date of assumption of their office will be the same date: April 1, 2017)

2. Reason for Change

Terumo has decided the change above in order to accelerate execution of new five-year Mid- to Long-term Growth Strategy under new management team.

About Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with over \$5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.

###